Durvalumab monotherapy demonstrated a favorable safety profile and comparable effectiveness to VEGF‐TKIs in patients with advanced HCC unsuitable for combination immunotherapy, especially for those with Child–Pugh B status. This evidence concerns the gene VEGFA and hepatocellular carcinoma.